VEC Vectura Group Plc

TIDMVEC

RNS Number : 0490K

Vectura Group plc

30 December 2020

Vectura Group appoints Jeanne Hecht and Jeanne Thoma to its Board of Directors

Chippenham, UK - 30 December 2020: Vectura Group plc (LSE: VEC) ("Vectura", the "Group", or the "Company"), an industry-leading specialist inhalation CDMO, is pleased to announce the appointments of Jeanne Hecht and Jeanne Thoma as Independent Non-Executive Directors of the Company with effect from 31(st) December 2020.

Jeanne Hecht was most recently CEO of Ora, Inc. ("Ora") a full-service pre-clinical and clinical ophthalmic drug and device development firm. Previously she served as Chief Operating Officer and was a Board Director of Median Technologies, a clinical services imaging business. Prior to this Jeanne had a substantial career with Quintiles (later IQVIA), the world's largest contract development services company, where she led global sales and strategic accounts.

Jeanne Thoma was most recently CEO and President of SPI Pharma, which provides specialist formulation and ingredient services to the pharmaceutical and nutritional industries, and is part of Associated British Foods plc. Previously she served as a senior advisor to the pharmaceutical industry, and has had successful careers with Lonza where, in her last role, she was President and Executive Committee Member, and BASF where she served in senior key commercial roles in their pharmaceutical solutions business. Jeanne is a member of the Boards of Directors of ANI Pharmaceuticals Inc, an integrated specialty pharmaceutical company, and Avid Bioservices Inc, a contract development and manufacturing organisation focused on the development and cGMP manufacturing of biopharmaceutical mammalian cell culture products.

Bruno Angelici, Chairman of Vectura, commented:

"I'm delighted to welcome Jeanne Hecht and Jeanne Thoma to the Board of Vectura. Jeanne Hecht brings significant experience in drug development services globally, which directly supports our new strategic direction as a leading inhalation CDMO. Jeanne Thoma brings a unique blend of commercial, HR and business leadership experience in pharmaceutical services, which will bring new domain expertise to our Board supporting our new business model."

Commenting on her appointment, Jeanne Hecht, said:

"I am pleased to join the Board of Vectura at this exciting time and look forward to helping the Board build on the Company's position as a leading development services business, helping the business deliver significant benefits to a growing number of customers and their patients."

Jeanne Thoma, said:

"As Vectura continues to build on its position as a leading inhalation specialist CDMO, I am excited to be working with the Board to help contribute to the Company's future growth."

There are no additional details to disclose under Listing Rule 9.6.13 (1) to (6) in respect of either appointment.

- Ends -

For more information, please contact:

 
Vectura Group plc 
David Ginivan - VP Corporate Communications         +44 (0)7471 352 720 
 Elizabeth Knowles - Director Investor Relations     +44 (0)7767 160 565 
 Consilium Strategic Communications                 +44 (0)20 3709 5700 
Mary-Jane Elliott / Susan Stuart / David Daley 
 

About Vectura

Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABUBDDCDDDGGC

(END) Dow Jones Newswires

December 30, 2020 02:00 ET (07:00 GMT)

Vectura (LSE:VEC)
Historical Stock Chart
From Mar 2024 to May 2024

Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024